Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation

Isabelle Sermet-Gaudelus

Source: Eur Respir Rev 2013; 22: 66-71
Journal Issue: March 2013 - 22 (127)
Disease area: Paediatric lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Isabelle Sermet-Gaudelus. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. Eur Respir Rev 2013; 22: 66-71

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis
Source: Eur Respir Rev 2013; 22: 58-65
Year: 2013



Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis
Source: Eur Respir J 2011; 37: 59-69
Year: 2011



Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation
Source: Eur Respir J 2016; 47:1697-1705
Year: 2016



Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles
Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019
Year: 2019



A novel CFTR mutation found in a Chinese cystic fibrosis patient
Source: Eur Respir J 2005; 26: Suppl. 49, 402s
Year: 2005

Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients
Source: Eur Respir J 2004; 23: 679-684
Year: 2004



Improved CFTR and lung function with VX-770, a novel investigational potentiator of CFTR, in subjects with the G551D-CFTR mutation
Source: Annual Congress 2010 - Cystic fibrosis: new targets for therapy and impact of viral infections
Year: 2010


Potentiating and correcting mutant CFTR in patients with cystic fibrosis
Source: Eur Respir Monogr 2014; 64: 129-149
Year: 2014


Late-breaking abstract: VX-770, an investigational CFTR potentiator, in subjects with CF and the G551D mutation
Source: Annual Congress 2011 - Cystic fibrosis: detection and monitoring of early lung disease
Year: 2011


Targeting CFTR as a therapy for cystic fibrosis
Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Year: 2010

CFTR: cystic fibrosis and beyond
Source: Eur Respir J 2014; 44: 1042-1054
Year: 2014



Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis
Source: Annual Congress 2013 –Cystic fibrosis: lung function and change of lung function in infants and children before and after treatment
Year: 2013


Atypical cystic fibrosis
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=38
Year: 2006

CFTR gene mutations detected in Japanese individuals with cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 716s
Year: 2006

High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and ΔF508
Source: Eur Respir J 2001; 17: 1181-1186
Year: 2001



Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease
Source: Eur Respir J 2009; 34: 772
Year: 2009


Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient
Source: Eur Respir J 2002; 19: 374-376
Year: 2002



Pharmacological treatment of the biochemical defect in cystic fibrosis airways
Source: Eur Respir J 2001; 17: 1314-1321
Year: 2001



Cystic fibrosis transmembrane conductance regulator pharmacotherapy
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=88
Year: 2006